Advancing host-directed therapy for tuberculosis

Toll-Like Receptor Triggering of a Vitamin D-Mediated Human Antimicrobial Response

Liu, P. T., Stenger, S., Li, H., Wenzel, L., Tan, B. H., Krutzik, S. R., Ochoa, M. T., Schauber, J., Wu, K., Meinken, C., et al. (2006) · Science · doi:10.1126/science.1123933 · Cited by 3,924

Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent

Keane, J., Gershon, S. K., Wise, R. P., Mirabile‐Levens, E., Kasznica, J. M., Schwieterman, W. D., Siegel, J. N., & Braun, M. M. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011110 · Cited by 3,683

Phosphorylation of ULK1 (hATG1) by AMP-Activated Protein Kinase Connects Energy Sensing to Mitophagy

Egan, D. F., Shackelford, D. B., Mihaylova, M. M., Gelino, S., Kohnz, R. A., Mair, W., Vasquez, D. S., Joshi, A., Gwinn, D. M., Taylor, R., et al. (2011) · Science · doi:10.1126/science.1196371 · Cited by 2,600

Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease

Ravikumar, B., Vacher, C., Berger, Z., Davies, J. E., Luo, S., Oroz, L. G., Scaravilli, F., Easton, D. F., Duden, R., O'Kane, C. J., et al. (2004) · Nature Genetics · doi:10.1038/ng1362 · Cited by 2,347

Autophagy Is a Defense Mechanism Inhibiting BCG and Mycobacterium tuberculosis Survival in Infected Macrophages

Gutierrez, M. G., Master, S. S., Singh, S. B., Taylor, G. A., Colombo, M. I., & Deretic, V. (2004) · Cell · doi:10.1016/j.cell.2004.11.038 · Cited by 2,252

Identification of a Primary Target of Thalidomide Teratogenicity

Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136

The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583

A Mutation in the Interferon-γ –Receptor Gene and Susceptibility to Mycobacterial Infection

Newport, M. J., Huxley, C. M., Huston, S., Hawrylowicz, C. M., Oostra, B. A., Williamson, R., & Levin, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612263352602 · Cited by 1,198

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes.

Sampaio, E. P., Sarno, E. N., Gallily, R., Cohn, Z. A., & Kaplan, G. (1991) · The Journal of Experimental Medicine · doi:10.1084/jem.173.3.699 · Cited by 1,191

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo‐controlled, 52‐week trial

Keystone, E. C., Kavanaugh, A. F., Sharp, J. T., Tannenbaum, H., Hua, Y., Teoh, L. S., Fischkoff, S. A., & Chartash, E. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20217 · Cited by 1,171

Host-directed therapies for bacterial and viral infections

Kaufmann, S. H. E., Dorhoi, A., Hotchkiss, R. S., & Bartenschlager, R. F. W. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.162 · Cited by 869

Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles

Singh, A. P., Biswas, A., Shukla, A., & Maiti, P. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0068-3 · Cited by 645

Heterogeneity in tuberculosis

Cadena, A. M., Fortune, S. M., & Flynn, J. L. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2017.69 · Cited by 502

A major role for ferroptosis in Mycobacterium tuberculosis –induced cell death and tissue necrosis

Amaral, E. P., Costa, D. L., Namasivayam, S., Riteau, N., Kamenyeva, O., Mittereder, L., Mayer-Barber, K. D., Andrade, B. B., & Sher, A. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20181776 · Cited by 464

Dynamic balance of pro‐ and anti‐inflammatory signals controls disease and limits pathology

Cicchese, J. M., Evans, S., Hult, C., Joslyn, L. R., Wessler, T., Millar, J. A., Marino, S., Cilfone, N. A., Mattila, J. T., Linderman, J. J., et al. (2018) · Immunological Reviews · doi:10.1111/imr.12671 · Cited by 344

Tuberculosis—advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers

Wallis, R. S., Maeurer, M. J., Mwaba, P., Chakaya, J. M., Rustomjee, R., Migliori, G. B., Marais, B. J., Schito, M. L., Churchyard, G., Swaminathan, S., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)00070-0 · Cited by 271

Mycobacterium tuberculosis induces decelerated bioenergetic metabolism in human macrophages

Cumming, B. M., Addicott, K. W., Adamson, J., & Steyn, A. J. C. (2018) · eLife · doi:10.7554/elife.39169 · Cited by 224

The Macrophage: A Disputed Fortress in the Battle against Mycobacterium tuberculosis

Queval, C. J., Brosch, R., & Simeone, R. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.02284 · Cited by 215

In vivo inhibition of tryptophan catabolism reorganizes the tuberculoma and augments immune-mediated control of Mycobacterium tuberculosis

Gautam, U. S., Foreman, T. W., Bucşan, A. N., Veatch, A. V., Alvarez, X. A., Adékambi, T., Golden, N., Gentry, K. M., Doyle‐Meyers, L. A., Russell‐Lodrigue, K., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1711373114 · Cited by 197

Tuberculosis following PD-1 blockade for cancer immunotherapy

Barber, D. L., Sakai, S., Kudchadkar, R. R., Fling, S. P., Day, T. A., Vergara, J. A., Ashkin, D., Cheng, J., Lundgren, L. M., Raabe, V., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aat2702 · Cited by 195

Significant Effects of Oral Phenylbutyrate and Vitamin D3 Adjunctive Therapy in Pulmonary Tuberculosis: A Randomized Controlled Trial

Mily, A., Rekha, R. S., Kamal, S. M. M., Arifuzzaman, A. S. M., Rahim, Z., Khan, L., Haq, M. A., Zaman, K., Bergman, P., Brighenti, S., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0138340 · Cited by 185

Host-Directed Therapeutic Strategies for Tuberculosis

Kolloli, A., & Subbian, S. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00171 · Cited by 164

Signaling pathways in macrophages: molecular mechanisms and therapeutic targets

Li, M., Wang, M., Wen, Y., Zhang, H., Zhao, G., & Gao, Q. (2023) · MedComm · doi:10.1002/mco2.349 · Cited by 165

Drug Resistance in Nontuberculous Mycobacteria: Mechanisms and Models

Saxena, S., Spaink, H. P., & Forn‐Cuní, G. (2021) · Biology · doi:10.3390/biology10020096 · Cited by 152

Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial

Wallis, R. S., Ginindza, S., Beattie, T., Arjun, N., Likoti, M., Edward, V., Rassool, M. S., Ahmed, K., Fielding, K., Ahidjo, B. A., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30448-3 · Cited by 152

Immunometabolism within the tuberculosis granuloma: amino acids, hypoxia, and cellular respiration

Qualls, J. E., & Murray, P. J. (2015) · Seminars in Immunopathology · doi:10.1007/s00281-015-0534-0 · Cited by 151

Host‐directed therapy to combat mycobacterial infections*

Kilinç, G., Saris, A., Ottenhoff, T. H. M., & Haks, M. C. (2021) · Immunological Reviews · doi:10.1111/imr.12951 · Cited by 148

PD-1 blockade exacerbates Mycobacterium tuberculosis infection in rhesus macaques

Kauffman, K. D., Sakai, S., Lora, N. E., Namasivayam, S., Baker, P. J., Kamenyeva, O., Foreman, T. W., Nelson, C. E., Oliveira-de-Souza, D., Vinhaes, C. L., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abf3861 · Cited by 151

Metformin Use Reverses the Increased Mortality Associated With Diabetes Mellitus During Tuberculosis Treatment

Degner, N. R., Wang, J., Golub, J. E., & Karakousis, P. C. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix819 · Cited by 136

Host sirtuin 1 regulates mycobacterial immunopathogenesis and represents a therapeutic target against tuberculosis

Cheng, C. Y., Gutierrez, N. M., Marzuki, M., Lu, X., Foreman, T. W., Paleja, B. S., Lee, B. T. K., Balachander, A., Chen, J., Tsenova, L., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aaj1789 · Cited by 138

Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review

Kiran, D., Podell, B. K., Chambers, M. A., & Basaraba, R. J. (2015) · Seminars in Immunopathology · doi:10.1007/s00281-015-0537-x · Cited by 135

Towards host-directed therapies for tuberculosis

Zumla, A. I., Chakaya, J. M., Höelscher, M., Ntoumi, F., Rustomjee, R., Vilaplana, C., Yeboah‐Manu, D., Rasolofo, V., Munderi, P., Singh, N., et al. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4696 · Cited by 125

The formulation of nanomedicines for treating tuberculosis

Costa, A., Pinheiro, M., Magalhães, J., Ribeiro, R., Seabra, V., Reis, S., & Sarmento, B. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.012 · Cited by 123

Antimycobacterial and Anti-inflammatory Mechanisms of Baicalin via Induced Autophagy in Macrophages Infected with Mycobacterium tuberculosis

Zhang, Q., Sun, J., Wang, Y., He, W., Wang, L., Zheng, Y., Wu, J., Zhang, Y., & Jiang, X. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.02142 · Cited by 124

Statin adjunctive therapy shortens the duration of TB treatment in mice

Dutta, N. K., Bruiners, N., Pinn, M. L., Zimmerman, M. D., Prideaux, B., Dartois, V. A., Gennaro, M. L., & Karakousis, P. C. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw014 · Cited by 112

Coating of a Novel Antimicrobial Nanoparticle with a Macrophage Membrane for the Selective Entry into Infected Macrophages and Killing of Intracellular Staphylococci

Li, Y., Liu, Y., Ren, Y., Su, L., Li, A., An, Y., Rotello, V. M., Zhang, Z., Wang, Y., Liu, Y., et al. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202004942 · Cited by 108

The Immune Mechanisms of Lung Parenchymal Damage in Tuberculosis and the Role of Host-Directed Therapy

Stek, C. J., Allwood, B., Walker, N. F., Wilkinson, R. J., Lynen, L., & Meintjes, G. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02603 · Cited by 105

Autophagy restricts Mycobacterium tuberculosis during acute infection in mice

Golovkine, G. R., Roberts, A. W., Morrison, H. M., Rivera‐Lugo, R., McCall, R. M., Nilsson, H., Garelis, N. E., Repasy, T., Cronce, M. J., Budzik, J. M., et al. (2023) · Nature Microbiology · doi:10.1038/s41564-023-01354-6 · Cited by 105

Cell death at the cross roads of host-pathogen interaction in Mycobacterium tuberculosis infection

Mohareer, K., Asalla, S., & Banerjee, S. (2018) · Tuberculosis · doi:10.1016/j.tube.2018.09.007 · Cited by 99

Influence of Genetic Polymorphism Towards Pulmonary Tuberculosis Susceptibility

Harishankar, M., Selvaraj, P., & Bethunaickan, R. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00213 · Cited by 103

MAIT cell-directed therapy of Mycobacterium tuberculosis infection

Sakai, S., Kauffman, K. D., Oh, S., Nelson, C. E., Barry, C. E., & Barber, D. L. (2020) · Mucosal Immunology · doi:10.1038/s41385-020-0332-4 · Cited by 93

Stem cell-based Lung-on-Chips: The best of both worlds?

Nawroth, J. C., Barrile, R., Conegliano, D., van Riet, S., Hiemstra, P. S., & Villenave, R. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.005 · Cited by 89

Doxycycline host-directed therapy in human pulmonary tuberculosis

Miow, Q. H., Vallejo, A. F., Wang, Y., Hóng, J., Bai, C. G., Teo, F. S. W., Wang, D. A., Loh, H. R., Tan, T. Z., Ding, Y., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci141895 · Cited by 86

Adjunctive vitamin D in tuberculosis treatment: meta-analysis of individual participant data

Jolliffe, D. A., Ganmaa, D., Wejse, C. M., Raqib, R., Haq, M. A., Salahuddin, N., Daley, P., Ralph, A. P., Ziegler, T. R., & Martineau, A. R. (2019) · European Respiratory Journal · doi:10.1183/13993003.02003-2018 · Cited by 85

Clinical Development of New TB Vaccines: Recent Advances and Next Steps

Hatherill, M., White, R. G., & Hawn, T. R. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.03154 · Cited by 85

Adjunctive Phosphodiesterase-4 Inhibitor Therapy Improves Antibiotic Response to Pulmonary Tuberculosis in a Rabbit Model

Subbian, S., Tsenova, L., Holloway, J., Peixoto, B., O’Brien, P. E., Dartois, V. A., Khetani, V. D., Zeldis, J. B., & Kaplan, G. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.01.015 · Cited by 82

The E3 ubiquitin ligase NEDD4 enhances killing of membrane-perturbing intracellular bacteria by promoting autophagy

Pei, G., Buijze, H., Liu, H., Moura‐Alves, P., Goosmann, C., Brinkmann, V., Kawabe, H., Dorhoi, A., & Kaufmann, S. H. E. (2017) · Autophagy · doi:10.1080/15548627.2017.1376160 · Cited by 86

IL-17RA in Non-Hematopoietic Cells Controls CXCL-1 and 5 Critical to Recruit Neutrophils to the Lung of Mycobacteria-Infected Mice during the Adaptive Immune Response

Lombard, R., Doz, E., Carreras, F., Epardaud, M., Vern, Y. L., Buzoni–Gatel, D., & Winter, N. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149455 · Cited by 81

Metformin enhances anti-mycobacterial responses by educating CD8+ T-cell immunometabolic circuits

Böhme, J., Martínez, N., Li, S., Lee, A., Marzuki, M., Tizazu, A. M., Ackart, D. F., Haugen, J. D., Todd, A., Lachmandas, E., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19095-z · Cited by 84

The effect of metformin on culture conversion in tuberculosis patients with diabetes mellitus

Lee, Y. J., Han, S. K., Park, J. H., Lee, J., Kim, D. K., Chung, H. S., & Heo, E. Y. (2018) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2017.249 · Cited by 79

Host Antimicrobial Peptides: The Promise of New Treatment Strategies against Tuberculosis

Arranz‐Trullén, J., Lu, L., Pulido, D., Bhakta, S., & Boix, E. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01499 · Cited by 77

Opportunities for Overcoming Mycobacterium tuberculosis Drug Resistance: Emerging Mycobacterial Targets and Host-Directed Therapy

Torfs, E., Piller, T., Cos, P., & Cappoen, D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20122868 · Cited by 72

Corticosteroids inhibit Mycobacterium tuberculosis-induced necrotic host cell death by abrogating mitochondrial membrane permeability transition

Gräb, J., Suárez, I., van Gumpel, E., Winter, S., Schreiber, F., Esser, A., Hölscher, C., Fritsch, M., Herb, M., Schramm, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08405-9 · Cited by 69

Modular Assembly of Host–Guest Metal–Phenolic Networks Using Macrocyclic Building Blocks

Pan, S., Guo, R., Bertleff‐Zieschang, N., Li, S., Besford, Q. A., Zhong, Q., Yun, G., Zhang, Y., Cavalieri, F., Ju, Y., et al. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201912296 · Cited by 66

Host-Directed Therapy as a Novel Treatment Strategy to Overcome Tuberculosis: Targeting Immune Modulation

Ahmed, S., Raqib, R., Gudmundsson, G. H., Bergman, P., Agerberth, B., & Rekha, R. S. (2020) · Antibiotics · doi:10.3390/antibiotics9010021 · Cited by 69

Metformin: Candidate host-directed therapy for tuberculosis in diabetes and non-diabetes patients

Restrepo, B. I. (2016) · Tuberculosis · doi:10.1016/j.tube.2016.09.008 · Cited by 63

Inhalable poly(lactic-co-glycolic acid) (PLGA) microparticles encapsulating all-trans-Retinoic acid (ATRA) as a host-directed, adjunctive treatment for Mycobacterium tuberculosis infection

O’Connor, G., Krishnan, N., Fagan-Murphy, A., Cassidy, J. P., O’Leary, S. M., Robertson, B. D., Keane, J., O’Sullivan, M. P., & Cryan, S. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.10.020 · Cited by 63

The Lipid Virulence Factors of Mycobacterium tuberculosis Exert Multilayered Control over Autophagy-Related Pathways in Infected Human Macrophages

Bah, A., Sanicas, M., Nigou, J., Guilhot, C., Astarie‐Dequeker, C., & Vergne, I. (2020) · Cells · doi:10.3390/cells9030666 · Cited by 65

Epigenetic Regulation of Matrix Metalloproteinase-1 and -3 Expression in Mycobacterium tuberculosis Infection

Moores, R., Brilha, S., Schutgens, F., Elkington, P. T., & Friedland, J. S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00602 · Cited by 65

Mycobacterium tuberculosis Modulates miR-106b-5p to Control Cathepsin S Expression Resulting in Higher Pathogen Survival and Poor T-Cell Activation

Pires, D., Bernard, E. M., Pombo, J. P., Carmo, N., Fialho, C., Gutierrez, M. G., Bettencourt, P., & Anes, E. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01819 · Cited by 61

Role of Sirt1 in innate immune mechanisms against Mycobacterium tuberculosis via the inhibition of TAK1 activation

Yang, H. S., Hu, J., Chen, Y., & Ge, B. (2019) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2019.04.006 · Cited by 60

Necrosis Driven Triglyceride Synthesis Primes Macrophages for Inflammation During Mycobacterium tuberculosis Infection

Jaisinghani, N., Dawa, S., Singh, K., Nandy, A., Menon, D., Bhandari, P. D., Khare, G., Tyagi, A. K., & Gandotra, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01490 · Cited by 58

Complex regulation of neutrophil-derived MMP-9 secretion in central nervous system tuberculosis

Ong, C. W. M., Pabisiak, P. J., Brilha, S., Singh, P., Roncaroli, F., Elkington, P. T., & Friedland, J. S. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0801-1 · Cited by 58

Trends in the discovery of new drugs for Mycobacterium tuberculosis therapy with a glance at resistance

Lohrasbi, V., Talebi, M., Bialvaei, A. Z., Fattorini, L., Drancourt, M., Heidary, M., & Darban‐Sarokhalil, D. (2017) · Tuberculosis · doi:10.1016/j.tube.2017.12.002 · Cited by 57

Regulation of phagocyte triglyceride by a STAT-ATG2 pathway controls mycobacterial infection

Péan, C. B., Schiebler, M., Tan, S. W. S., Sharrock, J., Kierdorf, K., Brown, K., Maserumule, C., Menezes, S., Pilátová, M., Bronda, K., et al. (2017) · Nature Communications · doi:10.1038/ncomms14642 · Cited by 55

Imbalance of NET and Alpha-1-Antitrypsin in Tuberculosis Patients Is Related With Hyper Inflammation and Severe Lung Tissue Damage

de Melo, M. G. M., Mesquita, E. D. D., Oliveira, M. M., da Silva-Monteiro, C., Silveira, A. K., Malaquias, T. D. S. S., Dutra, T. C. P., Galliez, R. M., Kritski, A. L., Silva, E., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03147 · Cited by 55

Ibrutinib suppresses intracellular mycobacterium tuberculosis growth by inducing macrophage autophagy

Hu, Y., Wen, Z., Liu, S., Cai, Y., Guo, J., Xu, Y., Lin, D., Zhu, J., Li, D., & Chen, X. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.03.003 · Cited by 56

Capture and visualization of live Mycobacterium tuberculosis bacilli from tuberculosis patient bioaerosols

Dinkele, R., Gessner, S., McKerry, A., Leonard, B., Seldon, R., Koch, A. S., Morrow, C. D., Gqada, M., Kamariza, M., Bertozzi, C. R., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009262 · Cited by 56

New role for FDA-approved drugs in combating antibiotic-resistant bacteria

Andersson, J. A., Fitts, E. C., Kirtley, M. L., Ponnusamy, D., Peniche, A. G., Dann, S. M., Motin, V. L., Chauhan, S., Rosenzweig, J. A., Sha, J., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00326-16 · Cited by 53

FOXO3 Transcription Factor Regulates IL-10 Expression in Mycobacteria-Infected Macrophages, Tuning Their Polarization and the Subsequent Adaptive Immune Response

Bouzeyen, R., Haoues, M., Barbouche, M., Singh, R., & Essafi, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02922 · Cited by 52

Mechanisms of lung damage in tuberculosis: implications for chronic obstructive pulmonary disease

Kayongo, A., Nyiro, B., Siddharthan, T., Kirenga, B., Checkley, W., Joloba, M. L., Ellner, J. J., & Salgame, P. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1146571 · Cited by 52

Autophagy in Mycobacterium tuberculosis and HIV infections

Espert, L., Beaumelle, B. D., & Vergne, I. (2015) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2015.00049 · Cited by 53

GM-CSF targeted immunomodulation affects host response to M. tuberculosis infection

Benmerzoug, S., Marinho, F. V., Rose, S., Mackowiak, C., Gosset, D., Sedda, D., Poisson, E., Uyttenhove, C., Snick, J. V., Jacobs, M., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-26984-3 · Cited by 51

Simvastatin Enhances the Immune Response Against Mycobacterium tuberculosis

Guerra-de-Blas, P. D. C., Bobadilla-del-Valle, M., Sada‐Ovalle, I., Estrada‐García, I., Torres‐González, P., Saavedra, A. L., Guzmán‐Beltrán, S., Ponce‐de‐León, A., & Sifuentes‐Osornio, J. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02097 · Cited by 50

Deficiency in the autophagy modulator Dram1 exacerbates pyroptotic cell death of Mycobacteria-infected macrophages

Zhang, R., Varela, M., Forn‐Cuní, G., Torraca, V., van der Vaart, M., & Meijer, A. H. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2477-1 · Cited by 50

Pharmacologic Inhibition of Host Phosphodiesterase-4 Improves Isoniazid-Mediated Clearance of Mycobacterium tuberculosis

Subbian, S., Koo, M.-S., Tsenova, L., Khetani, V. D., Zeldis, J. B., Fallows, D. A., & Kaplan, G. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00238 · Cited by 49

New drugs for the treatment of Mycobacterium tuberculosis infection

AlMatar, M., AlMandeal, H., Var, İ., Kayar, B., & Köksal, F. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.04.105 · Cited by 49

Elevated levels of matrix metalloproteinases reflect severity and extent of disease in tuberculosis-diabetes co-morbidity and are predominantly reversed following standard anti-tuberculosis or metformin treatment

Kumar, N. P., Moideen, K., Viswanathan, V., Shruthi, B. S., Sivakumar, S., Menon, P. A., Kornfeld, H., & Babu, S. (2018) · BMC Infectious Diseases · doi:10.1186/s12879-018-3246-y · Cited by 49

Host-directed therapies in pulmonary tuberculosis: Updates on anti-inflammatory drugs

Cubillos-Angulo, J. M., Nogueira, B. M. F., Arriaga, M. B., Barreto‐Duarte, B., Araújo‐Pereira, M., Fernandes, C. D., Vinhaes, C. L., Villalva-Serra, K., Nunes, V. M., Miguez-Pinto, J. P., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.970408 · Cited by 48

Targeting Innate-Like T Cells in Tuberculosis

Huang, S. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00594 · Cited by 48

Ohmyungsamycins promote antimicrobial responses through autophagy activation via AMP-activated protein kinase pathway

Kim, T. S., Shin, Y., Lee, H., Kim, J. K., Choe, J. H., Jang, J., Um, S., Jin, H. S., Komatsu, M., Cha, G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-03477-3 · Cited by 48

Toxoplasma gondii Dense Granule Proteins 7, 14, and 15 Are Involved in Modification and Control of the Immune Response Mediated via NF-κB Pathway

Ihara, F., Fereig, R. M., Himori, Y., Kameyama, K., Umeda, K., Tanaka, S., Ikeda, R., Yamamoto, M., & Nishikawa, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01709 · Cited by 47

Multiscale Model of Mycobacterium tuberculosis Infection Maps Metabolite and Gene Perturbations to Granuloma Sterilization Predictions

Pienaar, E., Matern, W. M., Linderman, J. J., Bader, J. S., & Kirschner, D. E. (2016) · Infection and Immunity · doi:10.1128/iai.01438-15 · Cited by 49

Impacts of metformin on tuberculosis incidence and clinical outcomes in patients with diabetes: a systematic review and meta-analysis

Zhang, M., & He, J.-Q. (2019) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-019-02786-y · Cited by 47

Host-Directed Therapies for Tackling Multi-Drug Resistant Tuberculosis: Learning From the Pasteur-Bechamp Debates: Table 1.

Zumla, A. I., & Maeurer, M. J. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ631 · Cited by 45

Host-directed drug therapy for tuberculosis

Guler, R., & Brombacher, F. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1917 · Cited by 45

The Role of Host Genetics (and Genomics) in Tuberculosis

Naranbhai, V. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.tbtb2-0011-2016 · Cited by 45

Interplay of DDP4 and IP-10 as a Potential Mechanism for Cell Recruitment to Tuberculosis Lesions

Blauenfeldt, T., Petrone, L., Nonno, F. D., Baiocchini, A., Falasca, L., Chiacchio, T., Bondet, V., Vanini, V., Palmieri, F., Galluccio, G., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01456 · Cited by 45

AntiBac-Pred: A Web Application for Predicting Antibacterial Activity of Chemical Compounds

Pogodin, P. V., Lagunin, A. A., Rudik, A. V., Druzhilovskiy, D. S., Filimonov, D. A., & Poroikov, V. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00436 · Cited by 47

Human Antimicrobial RNases Inhibit Intracellular Bacterial Growth and Induce Autophagy in Mycobacteria-Infected Macrophages

Lu, L., Arranz‐Trullén, J., Prats-Ejarque, G., Pulido, D., Bhakta, S., & Boix, E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01500 · Cited by 44

Targeting Batf2 for infectious diseases and cancer

Guler, R., Roy, S., Suzuki, H., & Brombacher, F. (2015) · Oncotarget · doi:10.18632/oncotarget.5576 · Cited by 45

M2 macrophages or IL-33 treatment attenuate ongoing Mycobacterium tuberculosis infection

Piñeros, A. R., Campos, L. W., da Fonseca, D. M., Bertolini, T. B., Gembre, A. F., Prado, R. Q., Alves-Filho, J. C., Ramos, S. G., Russo, M., & Bonato, V. L. D. (2017) · Scientific Reports · doi:10.1038/srep41240 · Cited by 44

The COX- inhibitor indomethacin reduces Th1 effector and T regulatory cells in vitro in Mycobacterium tuberculosis infection

Tonby, K., Wergeland, I., Lieske, N., Kvale, D., Taskén, K., & Dyrhol‐Riise, A. M. (2016) · BMC Infectious Diseases · doi:10.1186/s12879-016-1938-8 · Cited by 43

Host-Pathogen Interaction as a Novel Target for Host-Directed Therapies in Tuberculosis

Abreu, R. B., Giri, P. K., & Quinn, F. D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01553 · Cited by 44

Metformin Adjunctive Therapy Does Not Improve the Sterilizing Activity of the First-Line Antitubercular Regimen in Mice

Dutta, N. K., Pinn, M. L., & Karakousis, P. C. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00652-17 · Cited by 41

Remembering the Host in Tuberculosis Drug Development

Frank, D. J., Horne, D. J. D. L., Dutta, N. K., Shaku, M. T., Madensein, R., Hawn, T. R., Steyn, A. J. C., Karakousis, P. C., Kana, B. D., Meintjes, G., et al. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy712 · Cited by 41

Repurposing Tamoxifen as Potential Host-Directed Therapeutic for Tuberculosis

Boland, R., Heemskerk, M. T., Forn‐Cuní, G., Korbee, C. J., Walburg, K. V., Esselink, J. J., dos Santos, C. C., Barclay, A. M., van der Hoeven, D. C. M., van der Sar, E., et al. (2022) · mBio · doi:10.1128/mbio.03024-22 · Cited by 40

Stringent Response Factors PPX1 and PPK2 Play an Important Role in Mycobacterium tuberculosis Metabolism, Biofilm Formation, and Sensitivity to Isoniazid In Vivo

Chuang, Y.-M., Dutta, N. K., Hung, C., Wu, T. ‐., Rubin, H. N., & Karakousis, P. C. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01139-16 · Cited by 39

Reclaiming hijacked phagosomes: Hybrid nano-in-micro encapsulated MIAP peptide ensures host directed therapy by specifically augmenting phagosome-maturation and apoptosis in TB infected macrophage cells

Sharma, A., Vaghasiya, K., Gupta, P., Gupta, U. D., & Verma, R. K. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.11.046 · Cited by 39

Evaluation of the efficacy of valproic acid and suberoylanilide hydroxamic acid (vorinostat) in enhancing the effects of first-line tuberculosis drugs against intracellular Mycobacterium tuberculosis

Rao, M., Valentini, D., Zumla, A. I., & Maeurer, M. J. (2018) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2018.02.021 · Cited by 39

The New Frontier of Host-Directed Therapies for Mycobacterium avium Complex

Crilly, N. P., Ayeh, S. K., & Karakousis, P. C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.623119 · Cited by 39

Lactate Metabolism and Signaling in Tuberculosis and Cancer: A Comparative Review

Kiran, D., & Basaraba, R. J. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.624607 · Cited by 39

WNT6/ACC2-induced storage of triacylglycerols in macrophages is exploited by Mycobacterium tuberculosis

Brandenburg, J., Marwitz, S., Tazoll, S. C., Waldow, F., Kalsdorf, B., Vierbuchen, T., Scholzen, T. E., Groß, A., Goldenbaum, S., Hölscher, A., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci141833 · Cited by 38

The phosphatase PPM1A controls monocyte-to-macrophage differentiation

Smith, S. R., Schaaf, K., Rajabalee, N., Wagner, F., Duverger, A. E., Kutsch, O., & Sun, J. (2018) · Scientific Reports · doi:10.1038/s41598-017-18832-7 · Cited by 37

Achieving Optimal Health With Host‐Directed Therapies (HDTs) in Infectious Diseases—A New Horizon

Gholap, A. D., Khuspe, P. R., Pardeshi, S. R., Uddin, M. J., Das, U., Hatvate, N. T., Rojekar, S. V., Giram, P. S., Khalid, M., Choonara, Y. E., et al. (2024) · Advanced Therapeutics · doi:10.1002/adtp.202400169 · Cited by 36

Immune Cell Regulatory Pathways Unexplored as Host-Directed Therapeutic Targets for Mycobacterium tuberculosis : An Opportunity to Apply Precision Medicine Innovations to Infectious Diseases

Mahon, R. N., & Hafner, R. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ621 · Cited by 37

Risk score for predicting mortality including urine lipoarabinomannan detection in hospital inpatients with HIV-associated tuberculosis in sub-Saharan Africa: Derivation and external validation cohort study

Gupta‐Wright, A., Corbett, E. L., Wilson, D., van Oosterhout, J. J., Dheda, K. U. J., Huerga, H., Peter, J., Bonnet, M., Moyo, M., Grint, D. J., et al. (2019) · PLoS Medicine · doi:10.1371/journal.pmed.1002776 · Cited by 38

Host Immune-Metabolic Adaptations Upon Mycobacterial Infections and Associated Co-Morbidities

Llibre, A., Dedicoat, M. J., Burel, J. G., Demangel, C., O’Shea, M. K., & Mauro, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.747387 · Cited by 37

Roflumilast, a Type 4 Phosphodiesterase Inhibitor, Shows Promising Adjunctive, Host-Directed Therapeutic Activity in a Mouse Model of Tuberculosis

Maiga, M. C., Ahidjo, B. A., Maïga, M., & Bishai, W. R. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02145-15 · Cited by 36

A selective PPM1A inhibitor activates autophagy to restrict the survival of Mycobacterium tuberculosis

Berton, S., Chen, L., Liang, Y. C., Xu, Z., Afriyie-Asante, A., Rajabalee, N., Yang, W., & Sun, J. (2022) · Cell chemical biology · doi:10.1016/j.chembiol.2022.03.006 · Cited by 35

Host-Directed Therapeutics for Tuberculosis: Can We Harness the Host?

Hawn, T. R., Matheson, A. I., Maley, S. N., & Vandal, O. H. (2013) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00032-13 · Cited by 152

Exploring the potential of adjunct therapy in tuberculosis

Rayasam, G. V., & Balganesh, T. S. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.05.005 · Cited by 45

Host-directed therapies in pulmonary tuberculosis: Updates on anti-inflammatory drugs

Cubillos-Angulo, J. M., Nogueira, B. M. F., Arriaga, M. B., Barreto‐Duarte, B., Araújo‐Pereira, M., Fernandes, C. D., Vinhaes, C. L., Villalva-Serra, K., Nunes, V. M., Miguez-Pinto, J. P., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.970408 · Cited by 48

Host-Directed Therapies for Tuberculosis: Figure 1.Preprint

Tobin, D. M. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a021196 · Cited by 123

Metformin as Host-Directed Therapy for TB Treatment: Scoping Review

Naicker, N., Sigal, A., & Naidoo, K. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00435 · Cited by 55